Off the wire
Results of CBA playoffs  • China presses officials for cultural heritage protection  • Kenyan police launch manhunt for 4 terror suspects  • Roundup: High turnout in Iran's elections signal great expectations in post-sanctions era  • AU forces kill 10 Al-Shabaab militants in Somalia  • Head coach of Nigeria's senior soccer team resigns  • Parts of Sri Lanka face power cuts for 2nd day  • Feature: New Gucci collection takes fashion lovers to journey through creativity  • 2nd LD Writethru-China Headlines: China's housing market recovery patchy  • News Analysis: U.S. services sector contraction sees world's largest economy into recession  
You are here:   Home

1st Ld-Writethru: National plan issued to promote traditional Chinese medicine

Xinhua, February 26, 2016 Adjust font size:

China will develop traditional Chinese medicine (TCM) into a pillar industry, according to a blueprint released by the State Council, China's Cabinet, on Friday.

The plan proposes universal access to TCM care by 2020. By 2030, TCM should make a notably greater contribution to social and economic development.

The plan, calling for equal attention to TCM and Western medicine, set out tasks including "Internet + TCM", integrating TCM with elder care and tourism, protecting the inheritance of knowledge and technology, developing new drugs -- particularly those used in treating major communicable disease and severe illnesses -- and boosting industrialized production of drugs.

The plan proposes changes to the law and standardization, along with teaching TCM basics to primary and middle school students.

Apart from TCM, China also aspires to boost research and development of new drugs with indigenous intellectual property aspects in the 13th Five-year Plan.

China has made rapid progress in this field.

Liu Qian of the National Health and Family Planning Commission said the number of such new drugs developed during the 12th Five-Year Plan period (2011-2015) -- about 20 in total -- tripled those developed in the 50 years before, including the anti-tumor icotinib hydrochloride Chidamide and the inactivated EV71 vaccine against hand-foot-mouth disease. Endi